| Literature DB >> 35126876 |
Bo Wang1,2, Jayanta Mondal3, Piu Samui3, Amar Nath Chatterjee4, Abdullahi Yusuf5,6.
Abstract
In December 2019, a novel coronavirus disease (COVID-19) appeared in Wuhan, China. After that, it spread rapidly all over the world. Novel coronavirus belongs to the family of Coronaviridae and this new strain is called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epithelial cells of our throat and lungs are the main target area of the SARS-CoV-2 virus which leads to COVID-19 disease. In this article, we propose a mathematical model for examining the effects of antiviral treatment over viral mutation to control disease transmission. We have considered here three populations namely uninfected epithelial cells, infected epithelial cells, and SARS-CoV-2 virus. To explore the model in light of the optimal control-theoretic strategy, we use Pontryagin's maximum principle. We also illustrate the existence of the optimal control and the effectiveness of the optimal control is studied here. Cost-effectiveness and efficiency analysis confirms that time-dependent antiviral controlled drug therapy can reduce the viral load and infection process at a low cost. Numerical simulations have been done to illustrate our analytical findings. In addition, a new variable-order fractional model is proposed to investigate the effect of antiviral treatment over viral mutation to control disease transmission. Considering the superiority of fractional order calculus in the modeling of systems and processes, the proposed variable-order fractional model can provide more accurate insight for the modeling of the disease. Then through the genetic algorithm, optimal treatment is presented, and its numerical simulations are illustrated.Entities:
Year: 2022 PMID: 35126876 PMCID: PMC8803578 DOI: 10.1140/epjs/s11734-022-00454-4
Source DB: PubMed Journal: Eur Phys J Spec Top ISSN: 1951-6355 Impact factor: 2.891
Fig. 7Simulations of the SARS-CoV-2/COVID-19 model (3.3) showing the effect of the optimal strategies () for
Fig. 8Simulations of the SARS-CoV-2/COVID-19 model (3.3) showing the effect of the optimal strategies () for
Fig. 9Simulations of the SARS-CoV-2/ COVID-19 model (3.3) showing the effect of the optimal strategies () for
Fig. 5The system behaviour of Strategy I for fixed control ()
Fig. 6The system behaviour of Strategy II for fixed control ()
Fig. 10The time history of the proposed model with different variable-order fractional models when
Genetic algorithm configuration parameters
| Parameter | Value |
|---|---|
| Crossover fraction | 0.9 |
| Population size | 80 |
| Selection function | Tournament |
| Mutation function | Constraint-dependent |
| Crossover function | Intermediate |
| Migration direction | Forward |
| Migration fraction | 0.25 |
| Migration interval | 30 |
| Stopping criteria | 30, 000 |
Fig. 11The normalized value of best cost function
Fig. 12Simulations of the variable order fractional SARS-CoV-2/COVID-19 model (5.1) showing the effect of the optimal strategies
Variables and parameter values used for numerical simulations of the system (2.2)
| Variables and parameters | ||
|---|---|---|
| Dependent | Biological meaning | |
| Susceptible cells | ||
| Infected cells | ||
| Free virus | ||
| | ||
| Growth rate of cells | ||
| Carrying capacity of cell | ||
| Rate of infection/transmission | ||
| Efficacy of immunosuppressive drug | [0, 1] | |
| Efficacy of antiviral drug | [0, 1] | |
| Death rate of epithelial cell | ||
| Number of free virus produced | ||
| from infected cells | ||
| Virus removal rate |
Sensitivity indices of basic reproduction number ()
| Parameter | Description | Sensitivity index |
|---|---|---|
| Carrying capacity of cell | 1.0000 | |
| Rate of infection/transmission | 1.0000 | |
| Number of free virus produced | 1.0000 | |
| Virus removal rate | ||
| Efficacy of immunosuppressive drug | ||
| Efficacy of antiviral drug |
Description of the different control strategies
| Strategies | Description |
|---|---|
| I | Antiviral drug blocking infection |
| II | Antiviral drug blocking production of viral particles |
| III | Combination of antiviral drugs blocking infection and production |
Efficiency index for system (3.3)
| Strategy | | |
|---|---|---|
| No control | ||
| I | ||
| II | ||
| III |
| Strategies | Total infection averted | Total cost | ICER |
|---|---|---|---|
| No control | 0 | 0 | - |
| I | 252.21 | 7231 | 28.67 |
| II | 317.74 | 6888 | -5.2342 |
| III | 798.90 | 1155 | -11.9189 |
| Strategies | Total infection averted | Total cost | ICER |
|---|---|---|---|
| II | 317.74 | 6888 | 21.6800 |
| III | 798.90 | 1155 | -11.9149 |